Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 6, 2025British Journal of HaematologyOpen Access

Real‐world analysis of CPX ‐351 in AML ‐ MR : A multicentre study from the MARROW consortium

View Full Paper
Ask AI
Bookmark
Share

Authors

DPD. PetersCFCharles FoucarJAJustice Ameyi

Discussion

Loading...

Member takes

Overview

Retrospective analysis highlights clinical outcomes in 235 patients with acute myeloid leukaemia, suggesting benefits of CPX-351 and stem cell transplant.

Key Points

  • Complete remission rate of CPX-351 was 52% in acute myeloid leukaemia patients, indicating effective treatment.
  • Among responders, 55% underwent haematopoietic stem cell transplant to improve survival rates.
  • Retrospective study included 235 adults with newly diagnosed acute myeloid leukaemia across seven US centers.
  • Favourable clinical outcomes support molecular classification for treatment strategy in acute myeloid leukaemia.

Cite This Study

Peters et al. (2025) studied this question.

synapsesocial.com/papers/69337cfbb3f947a0a125a5d2https://doi.org/10.1111/bjh.70274
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CPX-351 is effective in secondary Acute Myeloid Leukemia, regardless if defined according to 2016 or 2022 edition of who classification.2025
  2. 2Prognostic relevance of mutational profile in secondary Acute Myeloid Leukemia patients treated with CPX-351.2025
  3. 3Outcomes with liposomal daunorubicin/cytarabine – a single-center experience2025
  4. 4Real World Study on the Best <scp>CPX</scp>‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation2025 · 6 citations
  5. 5Molecular response of Acute Myeloid Leukemia to induction with CPX-351 and its impact on prognosis2025